Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".

Authors :: Jamialahmadi O
Bianco C
Pelusi S
Romeo S
Valenti L
Source :: Journal of hepatology [J Hepatol] 2021 Jun; Vol. 74 (6), pp. 1494-1496. Date of Electronic Publication: 2021 Mar 05.
Publication Year :: 2021
Abstract: Competing Interests: Conflict of interest The authors declare that they have no conflict of interest relevant to the present study. LV has received speaking fees from MSD, Gilead, AlfaSigma and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics and Ionis Pharmaceuticals, and received research grants from Gilead. SR has served as a consultant for AstraZeneca, Celgene, Sanofi, Amgen, Akcea Therapeutics, Camp4, Ambys, Medacorp, Novartis and Pfizer in the past 5 years, and received research grants from AstraZeneca, Sanofi and Amgen. Please refer to the accompanying ICMJE disclosure forms for further details.

Subjects :: Humans
Liver Cirrhosis
Risk Factors
Carcinoma, Hepatocellular diagnosis
Carcinoma, Hepatocellular epidemiology
Carcinoma, Hepatocellular etiology
Liver Neoplasms diagnosis
Liver Neoplasms epidemiology
Liver Neoplasms etiology
Non-alcoholic Fatty Liver Disease complications
Non-alcoholic Fatty Liver Disease diagnosis
Non-alcoholic Fatty Liver Disease epidemiology

Full Text Access

Tools